



Biology of Blood and Marrow Transplantation

journal homepage: www.bbmt.org



Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation



Claudio G. Brunstein¹, Marcelo C. Pasquini^{2,*}, Soyoung Kim^{2,3}, Mingwei Fei², Kehinde Adekola⁴, Ibrahim Ahmed⁵, Mahmoud Aljurf⁶, Vaibhav Agrawal⁷, Jeffrey J. Auletta⁸, Mino Battiwalla⁹, Nelli Bejanyan¹⁰, Joseph Bubalo¹¹, Jan Cerny¹², Lynette Chee¹³, Stefan O. Ciurea¹⁴, Cesar Freytes¹⁵, Shahinaz M. Gadalla¹⁶, Robert Peter Gale¹⁷, Siddhartha Ganguly¹⁸, Shahrukh K. Hashmi^{19,6}, Peiman Hematti²⁰, Gerhard Hildebrandt²¹, Leona A. Holmberg²², Oscar B. Lahoud²³, Heather Landau²³, Hillard M. Lazarus²⁴, Marcos de Lima²⁵, Vikram Mathews²⁶, Richard Maziarz¹¹, Taiga Nishihori¹⁰, Maxim Norkin²⁷, Richard Olsson^{28,29}, Ran Reshef³⁰, Seth Rotz³¹, Bipin Savani³², Harry C. Schouten³³, Sachiko Seo³⁴, Baldeep M. Wirk³⁵, Jean Yared³⁶, Shin Mineishi³⁷, John Rogosheske¹, Miguel-Angel Perales³⁸

¹ Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA

² CIBMTR[®] (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

³ Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA

⁴ Division of Hematology/Oncology, Department of Medicine and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

⁵ Department of Hematology Oncology and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, MO, USA

⁶ Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia

⁷ Division of Hematology/Oncology, Indiana University Simon Cancer Center, Indianapolis, IN, USA

⁸ Blood and Marrow Transplant Program and Host Defense Program, Divisions of Hematology/Oncology/Bone Marrow Transplant and Infectious Diseases, Nationwide Children's Hospital, Columbus, OH, USA

⁹ Hematology Branch, Sarah Cannon BMT Program, Nashville, TN, USA

¹⁰ Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

¹¹ Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA

¹² Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, MA, USA

¹³ The Royal Melbourne Hospital, Melbourne, Australia

¹⁴ University of Texas and MD Anderson Cancer Center, Houston, TX, USA

¹⁵ Texas Transplant Institute, San Antonio, TX, USA

¹⁶ Division of Cancer Epidemiology & Genetics, NIH-NCI Clinical Genetics Branch, Rockville, MD, USA

¹⁷ Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom

¹⁸ Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS, USA

¹⁹ Department of Internal Medicine, Mayo Clinic, MN, USA

²⁰ Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI, USA

²¹ Markey Cancer Center, University of Kentucky, Lexington, KY, USA

²² Fred Hutchinson Cancer Research Center, Seattle, WA, USA

²³ Bone Marrow Transplant Service, Division of Hematology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

²⁴ Case Western Reserve University, Cleveland, OH, USA

²⁵ Department of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA

²⁶ Department of Hematology, Christian Medical College & Hospital, Vellore, India

²⁷ Division of Hematology/Oncology, University Florida College of Medicine, Gainesville, FL, USA

²⁸ Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

²⁹ Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden

³⁰ Blood and Marrow Transplantation Program and Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA

³¹ Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

³² Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

³³ Department of Hematology, Academische Ziekenhuis, Maastricht, Netherlands

³⁴ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

³⁵ Stony Brook University Medical Center, Stony Brook, NY, USA

Financial disclosure: See Acknowledgments on page 486.

* Correspondence an reprint requests: Marcelo C. Pasquini, MD, MS, Medical College of Wisconsin, Department of Medicine, CIBMTR, 9200 West Wisconsin Avenue, CC5500, Milwaukee, WI 53226.

E-mail address: mpasquini@mcw.edu (M.C. Pasquini).

³⁶ Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA

³⁷ Penn State Health Hershey Medical Center, Hershey, PA, USA

³⁸ Adult Bone Marrow Transplant Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Article history:

Received 29 June 2018

Accepted 6 November 2018

Key Words:

Obesity

Conditioning regimen

Autologous hematopoietic cell transplantation

A B S T R A C T

Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index (BMI) ≥ 30 kg/m². Dose adjustment was defined as a reduction in standard dosing $\geq 20\%$, based on ideal, reported dosing and actual weights. We included 2 groups of US patients who had received autoHCT between 2008 and 2014. Specifically, we included patients with multiple myeloma (MM, n = 1696) treated with high-dose melphalan and patients with Hodgkin or non-Hodgkin lymphomas (n = 781) who received carmustine, etoposide, cytarabine, and melphalan conditioning. Chemotherapy dose was adjusted in 1324 patients (78%) with MM and 608 patients (78%) with lymphoma. Age, sex, BMI, race, performance score, comorbidity index, and disease features (stage at diagnosis, disease status, and time to transplant) were similar between dose groups. In multivariate analyses for MM, adjusting for melphalan dose and for center effect had no impact on overall survival ($P = .894$) and treatment-related mortality (TRM) ($P = .62$), progression ($P = .12$), and progression-free survival (PFS; $P = .178$). In multivariate analyses for lymphoma, adjusting chemotherapy doses did not affect survival ($P = .176$), TRM ($P = .802$), relapse ($P = .633$), or PFS ($P = .812$). No center effect was observed in lymphoma. This study demonstrates that adjusting chemotherapy dose before autoHCT in obese patients with MM and lymphoma does not influence mortality. These results do not support adjusting chemotherapy dose in this population.

© 2018 American Society for Blood and Marrow Transplantation.

INTRODUCTION

Obesity incidence has been increasing steadily in recent years [1–3]. The American Society of Clinical Oncology guidelines recommended chemotherapy dosing based on actual body weight (ABW) for obese patients treated with curative-intent [4] chemotherapy in solid tumors. In contrast, hematopoietic cell transplantation (HCT) requires higher doses of chemotherapy, and practices of adjusting the weight because of concerns of organ toxicity are common [5,6]. In 2014 the American Society for Blood and Marrow Transplant completed an extensive review of the literature and published recommendations on chemotherapy dosing in obese patients [5]. That review focused on the effect of chemotherapy dosing on survival and toxicity and included comparisons between obese and nonobese patients. Yet, the recommendations were limited by the paucity of data in this population.

The complex clinical context of HCT, particularly allogeneic HCT, makes it difficult to isolate the impact of dose adjustment. Autologous HCT is associated with low treatment-related mortality (TRM), but relapse remains the main cause of treatment failure. The potentially lower “background noise” and more uniform conditioning regimens across transplant centers make autologous HCT a better setting for exploring the impact of adjusted doses. Additionally, chemotherapy doses in autologous HCT are generally much higher than for standard cancer treatment, so it is important to know whether obese patients have a higher toxicity when doses are based on ABW.

Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) show that many, but not all, transplant centers adjust chemotherapy dose for obese patients, and dose-adjustment practices vary widely. This study compares outcomes for obese patients whose chemotherapy dose was adjusted. Specifically, we compared outcomes for patients with multiple myeloma (MM) treated with high-dose melphalan and patients with Hodgkin or non-Hodgkin lymphomas who received carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning.

METHODS

Data Sources

The CIBMTR is a working group of more than 500 transplantation centers worldwide that contribute detailed data on HCT to a statistical center at the

Medical College of Wisconsin. The CIBMTR is a research collaboration between the National Marrow Donor Program/Be The Match and the Medical College of Wisconsin. Participating centers are required to report all transplantations consecutively; patients are followed longitudinally, and compliance is monitored by onsite audits. Data quality is ensured, both by computerized checks for discrepancies and by physicians' review of submitted data. The CIBMTR conducts observational studies and complies with all applicable federal regulations that protect human subjects.

The CIBMTR collects data at 2 levels: Transplant Essential Data (TED) and Comprehensive Report Form (CRF) data. TED-level data include disease, age, sex, pre-HCT disease stage and chemotherapy responsiveness, date of diagnosis, graft type (bone marrow- and/or blood-derived stem cells), conditioning regimen, post-transplant disease progression and survival, development of a new malignancy, and cause of death. All CIBMTR centers contribute TED-level data. More detailed CRF-level data are collected on a subset of patients selected by a weighted randomization scheme. TED- and CRF-level data are collected pretransplant and then post-transplant at 100 days, at 6 months, annually until year 6, and biannually thereafter until death. Data for the current analysis were retrieved from CIBMTR (TED and CRF) report forms.

Patients

Adult patients aged ≥ 18 years with a body mass index (BMI) ≥ 30 kg/m² undergoing a first autologous HCT for MM or lymphoma performed in US centers between 2008 and 2014 were included in this study. BMI was calculated based on reported pretransplant actual weight and height. Additional eligibility included only those patients with MM receiving a single-drug melphalan (200 mg/m²) conditioning regimen and only those with lymphoma receiving a conditioning regimen with BEAM. The determination of chemotherapy dose reduction in patients with lymphoma receiving BEAM was based on the actual dose of melphalan.

Study Design

This was a retrospective, registry-based study. To determine whether the dose of chemotherapy had been adjusted, we looked at 3 possible measures: pretransplant ABW, dosing weight (DW), and calculated ideal body weight (IBW). We considered a patient to have received an adjusted dose if the DW was $<80\%$ of ABW.

Two groups were defined: (1) an unadjusted group, which dosed chemotherapy using actual weight, and (2) an adjusted group, which dosed chemotherapy using an adjusted weight based on the difference between IBW and actual weight. The degree of adjustment (adjusted factor β) varied across centers and was determined based on the following formula: $DW = IBW + (\text{adjusted factor } \beta) \times (ABW - IBW)$. DW is the same as adjusted body weight used to calculate chemotherapy dosing. Because the biology and outcomes of MM and lymphoma are significantly different, we performed the analyses for the whole group and separately for MM and lymphoma.

Endpoints and Definitions

As a surrogate for treatment-related toxicity, we used duration of hospitalization within the first 100 days after HCT. The HCT-specific comorbidity

index (HCT-Cl) [7] was calculated excluding obesity. Because many centers perform autologous HCT as an outpatient procedure or a hybrid, in which the hospitalization is limited to the period when patients receive chemotherapy, we considered only hospitalizations of >7 days.

TRM was defined as any death in the absence of disease relapse or progression. Patients who died in the first 28 days post-transplant without reported disease relapse or progression were considered to have TRM. Relapse or progression was the competing risk for this event. Disease relapse or progression was defined by the transplant center either as morphologic or radiologic relapse. For patients without relapse or progression information for whom the reported cause of death was the primary disease, we considered them to have relapse or progression, and the date was input as the day before the date of death. TRM was the competing risk for this event. Progression-free survival (PFS) was defined as freedom from death, relapse, or progression of the disease for which the patient received the autologous HCT. Living patients were censored at last follow-up. Overall survival (OS) was defined as death from any cause after HCT; living patients were censored at last follow-up.

Variables tested in the multivariate analyses were dose adjustment (main effect), +age (18 to 49, 50 to 59, >60 years), sex, Karnofsky performance status (KPS) score ($\geq 90\%$ versus $<90\%$), HCT-Cl excluding obesity (0, 1 to 2, or ≥ 3), BMI (30 to 34, 35 to 39, or ≥ 40 kg/m²), year of transplant, and time from diagnosis to HCT (<6, 6 to 12, 13 to 24, or >24 months). Additional disease-specific variables included International Staging System [8] at time of diagnosis (I to II or III) and disease status at transplant (complete response, partial response, or stable disease/progression) for MM and lymphoma subtype (non-Hodgkin lymphoma or Hodgkin lymphoma) and prior chemotherapy response (sensitive or resistant) for lymphoma.

Statistical Analysis

Patient-related and transplant-related factors were compared between dose-adjusted and -unadjusted cohorts using the chi-square test for categorical variables and the Mann-Whitney test for continuous variables. The Mann-Whitney test was selected to accommodate continuous variables without normal distribution. Probabilities for TRM and disease relapse were calculated, using cumulative incidence function accounting for competing risks and compared using Gray's test. PFS and OS were calculated using the Kaplan-Meier estimator and compared using log-rank test.

Multivariate analysis of the 4 major outcomes were done using Cox regression analysis, using the chemotherapy dose-adjustment covariate as the main effect and forced in all models. The 4 outcomes were TRM, disease progression or relapse, treatment failure, and overall mortality.

Each variable was tested for proportional hazard assumption. If assumption was violated, the variable was included as a time-dependent variable. To identify the significant risk factors, stepwise forward selection with a significance level of .05 was used to define variables with a significant association with the outcome. Sensitivity analysis with significance level of .1 was also tested, which did not change the variables selected on the final models. Interaction terms were examined between the chemotherapy dose-adjustment covariate and other significant covariates. Separate analyses were conducted for patients with MM and lymphoma. Dose-adjustment practices were done according to transplant center guidelines, which may result in a significant center effect, because individual cases cannot be considered independently. Center effects were tested using the score test and adjusted using a marginal model [9]. Analysis were done using SAS, version 9.4 (SAS Institute, Cary, NC).

RESULTS

Patients and Transplant Characteristics

Patient, disease, and transplant characteristics for patients with MM (n = 1696) and lymphoma (n = 781) are summarized in Table 1.

Among patients with MM, most patients had their melphalan dose reduced (78%). The median age, sex, KPS score, HCT-Cl, and BMI were similar between the groups that had chemotherapy adjusted or unadjusted. Disease characteristics including MM stage, disease status at transplantation, median time from diagnosis to transplantation, and year of transplantation were also similar between the 2 groups. The median adjustment factor for melphalan was 25% (ie, the DW was the IBW plus 25% of the difference between IBW and ABW). Cytogenetic markers and induction therapy were only available for a subgroup of patients with CRF-level data (n = 1094) and were not considered.

Among patients with lymphoma, chemotherapy adjustment was done on 78% of patients. The groups of patients whose chemotherapy was adjusted or unadjusted were similar in terms of median age, sex, KPS score, HCT-Cl, BMI, lymphoma

subtype, chemotherapy sensitivity before transplantation, median time from diagnosis to transplantation, and year of transplantation. Median chemotherapy adjustment factor based on melphalan dosing in BEAM was 26%. In a subgroup of patients with CRF-level reporting (n = 407), the distribution of staging at diagnosis and number of prior lines of therapy were similar between dose-adjustment groups.

Effect of Chemotherapy Adjustment on Length of Hospital Stay

As a surrogate measure of treatment-related toxicity, the proportion of patients hospitalized > 7 days in the first 100 days post-transplantation was compared between the dose-adjustment groups. The length of hospitalization was available for 1042 patients with MM and 459 with lymphoma. Seventy-eight percent of patients received dose-adjusted chemotherapy, with a median length of hospitalization in the first 100 days of 14 days (range, 8 to 72), in contrast to 15 days (range, 8 to 70) in those with unadjusted chemotherapy dose (P = .20). A higher proportion of patients with MM who received unadjusted doses of chemotherapy had a hospital stay longer than 15 days (P = .04). The same was not observed among patients with lymphoma (P = .59) (see Supplementary Table S1).

Effect of Chemotherapy Adjustment on Outcomes of All Patients

To maximize the power to detect slight differences, the impact of dose adjustment was tested on all patients, with results shown in Figure 1 and summarized in Supplementary Table S2. Multivariate analyses of overall mortality demonstrated a hazard ratio (HR) of 1.05 (95% confidence interval [CI], .89 to 1.24; P = .58). Younger age, KPS ≥ 90 , HCT-Cl < 3, and chemotherapy-sensitive disease were independent predictors of lower mortality for the whole study population. There was also no effect of dose adjustment on TRM (HR, 1.09; 95% CI, .52 to 2.29; P = 0.83) and treatment failure (HR, .86; 95% CI, .71 to 1.06; P = 0.16). Younger age, KPS ≥ 90 , and a diagnosis of myeloma were independent predictors of lower risk TRM. The independent predictors of lower hazards of treatment failure were female sex, KPS ≥ 90 , chemotherapy-sensitive disease, and disease. In contrast, there was a time-dependent effect of chemotherapy dose adjustment on the risk of relapse: Patients who received full-dose conditioning regimens had a 43% lower relapse hazard within 5 months post-HCT (HR, .57; 95% CI, .37 to .89; P = .01) and similar relapse hazard thereafter (>5 months; HR, 1.0; 95% CI, .84 to 1.19; P = .96).

The impact of disease in the relapse model varied over time. The relapse hazard for both diseases was the same in the first 8 months post-HCT (HR, .98; 95% CI, .81 to 1.18; P = .79). However, after 8 months relapses were less common among patients with lymphoma compared with MM (HR, .32; 95% CI, .27 to .38; P < .01). Female sex and chemotherapy-sensitive disease also independently predicted a lower hazard of relapse. In addition, because chemotherapy adjustment varied by center, for patients with MM a statistically significant center effect was observed on TRM (P = .023), PFS (P < .001), and relapse (P < .001) but not in survival (P = .66). For patients with lymphoma, no center effect was observed on any outcomes. The causes of death were similar whether there were chemotherapy dose adjustments or not (Table 2).

Effect of Chemotherapy Adjustment on Outcomes of Patients with MM

The 2-year OS probabilities were 88% (95% CI, 87% to 90%) and 89% (95% CI, 85% to 92%; P = .92) and PFS were 45% (95% CI,

Table 1
Patients and Transplant Characteristics of Obese Patients by DW

Variable	MM			Lymphoma		
	Adjusted Weight	Actual Weight	P	Adjusted Weight	Actual Weight	P
Number of patients	1324	372		609	172	
Number of centers	103	69		74	51	
Age, median, yr (range)	58 (20-76)	58 (33-77)	.66	55 (18-76)	55 (18-77)	.89
Male sex	747 (56)	210 (56)	.99	380 (62)	102 (59)	.46
Race			.08			.80
White	954 (72)	245 (66)		512 (84)	148 (86)	
Black	322 (24)	115 (31)		78 (13)	21 (12)	
Others	22 (2)	5 (1)		12 (2)	2 (1)	
Not reported	26 (2)	7 (2)		7 (1)	1 (<1)	
KPS score ≥ 90%	753 (57)	202 (54)	.66	378 (62)	111 (65)	<.001
HCT-Cl			.12			.28
No comorbidity except obesity	518 (39)	151 (41)		229 (38)	76 (44)	
1-2	414 (31)	134 (36)		194 (32)	48 (28)	
≥3	390 (29)	86 (23)		181 (30)	48 (28)	
Not reported	2 (<1)	1 (<1)		5 (<1)	0	
BMI kg/m ²			.08			
Median (range)	34 (30-80)	34 (30-88)		34 (30-70)	34 (30-80)	
30-34	768 (58)	240 (65)		333 (55)	102 (59)	
35-39	342 (26)	82 (22)		146 (24)	39 (23)	
≥40	214 (16)	50 (13)		130 (21)	31 (18)	
DW adjusted factor β, %*			<.001			<.001
Median (range)	25 (0-79)	100 (90-100)		26 (0-80)	100 (100)	
<30%	888 (67)	0		326 (54)	0	
30-79%	376 (33)	0		283 (46)	0	
80-89%	0	52 (14)		0	0	
90-100%	0	320 (86)		0	172 (100)	
Disease			.70			.98
MM, IgG	784 (59)	214 (58)				
MM, IgA	266 (20)	78 (21)				
MM, IgD	7 (<1)	2 (<1)				
MM, IgE	1 (<1)	0				
MM, IgM	8 (<1)	4 (1)				
MM, light chain	238 (18)	64 (17)				
MM, nonsecretory	20 (2)	10 (3)				
DLBCL				225 (37)	65 (38)	
Follicular NHL				68 (11)	21 (12)	
Mantle cell NHL				86 (14)	22 (13)	
Other B cell NHL				40 (7)	9 (5)	
T cell NHL				47 (8)	14 (8)	
HL				143 (23)	41 (24)	
MM stage at diagnosis			.01			
III	655 (49)	185 (50)				
I-II	595 (45)	180 (48)				
Not reported	74 (6)	7 (2)				
MM status before HCT			.32			
Complete remission	206 (16)	69 (19)				
Partial response	966 (73)	266 (72)				
Stable/relapse/progression	152 (11)	37 (10)				
Lymphoma status before HCT						.34
Chemotherapy-sensitive [†]				560 (92)	162 (94)	
Chemotherapy-resistant [‡]				42 (7)	7 (4)	
PIF/REL sensitivity unknown				7 (1)	3 (2)	
Conditioning regimen						
Melphalan dose, median, mg/kg (range)	4 (3-5)	4 (2-5)	.06	3 (2-8)	3 (<1-10)	.84
Actual melphalan dose, median, mg (range)	436 (307-704)	435 (163-619)	.10	318 (179-1035)	307 (26-962)	.004
Median time from diagnosis to transplant, mo (range)	8 (<1-183)	8 (3-763)	.17	16 (0-271)	17 (1-180)	.87
Transplant year			.003			.70
2008-2010	541 (41)	145 (39)		316 (52)	85 (49)	
2011-2012	405 (30)	89 (24)		114 (19)	37 (22)	
2013-2014	378 (29)	138 (37)		179 (29)	50 (29)	
Median follow-up of survivors, mo (range)	52 (1-103)	59 (2-101)		55 (2-110)	59 (1-101)	

Values are n (%) unless otherwise defined. DLBCL indicates diffuse large B cell lymphoma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; PIF primary induction failure; REL, relapse.

* DW adjusted factor β: adjusted DW = IBW + (adjusted factor β) × (ABW – IBW).

[†] Chemotherapy-sensitive: complete remission, partial remission, relapse/progression or never in remission and sensitive to prior treatment immediately before conditioning.

[‡] Chemotherapy-resistant: relapse/progression or never in remission and resistant to prior treatment immediately before conditioning.




Figure 1. Multivariate analysis comparing unadjusted with adjusted doses of chemotherapy before autologous HCT for patients with MM, lymphoma, and all patients. **In the combined population the effect of dose adjustment on disease relapse was significant in the first 5 months after transplant and not significant beyond 5 months.

42% to 48%) and 50% (95% CI, 45% to 55%; $P = .08$) for adjusted and unadjusted groups, respectively (Figure 2). Corresponding 2-year cumulative incidences of disease progression were 54% (95% CI, 51% to 56%) and 48% (95% CI, 43% to 53%; $P = .002$) and of TRM were 1% (95% CI, 1% to 2%) and 2% (95% CI, 1% to 4%; $P = .29$) (Figure 2). Multivariate analyses were carried out adjusting for center effect on overall mortality (HR, 1.01; 95% CI, .83 to 1.25; $P = .89$), treatment failure (HR, .85; 95% CI, .68 to 1.08; $P = .1784$), disease progression (HR, .84, 95% CI, .67 to 1.05; $P = 0.12$), and TRM (HR, 1.31; 95% CI, .45 to 3.79; $P = .62$) of unadjusted compared with dose-adjusted chemotherapy groups (Figure 1). Additional covariates associated with these outcomes are shown on Supplementary Table S3.

Effect of Chemotherapy Adjustment on Outcomes of Patients with Lymphoma

The 2-year OS probabilities were 79% (95% CI, 76% to 83%) and 82% (95% CI, 75% to 87%; $P = .51$) and PFS were 59% (95% CI, 55% to 63%) and 61% (95% CI, 54% to 68%; $P = .57$) for adjusted and unadjusted groups, respectively (Figure 3). Corresponding 2-year cumulative incidences of disease progression were 38%

(95% CI, 34% to 42%) and 34% (95% CI, 27% to 41%; $P = .35$) and of TRM were 3% (95% CI, 2% to 5%) and 5% (95% CI, 2% to 9%; $P = .42$) (Figure 3). Multivariate analyses were carried out on overall mortality (HR, 1.23; 95% CI, .91 to 1.66; $P = .176$), treatment failure (HR, 1.03; 95% CI, .81 to 1.30; $P = .812$), disease progression (HR, 1.06; 95% CI, .83 to 1.36; $P = .633$), and TRM (HR, .91; 95% CI, .44 to 1.90; $P = .802$) of unadjusted compared with adjusted chemotherapy groups (Figure 1). Additional covariates associated with these outcomes are shown on Supplementary Table S3.

DISCUSSION

High-dose chemotherapy with autologous HCT is the standard of care for patients with MM and subsets of lymphoma. The active therapy in autologous HCT is the high dose of chemotherapy, whereas the autologous graft serves as a supportive measure to accelerate hematopoietic recovery. Thus, chemotherapy dosing is critical.

Our study compares the effect of adjusted doses (or reducing the dose by using an adjusted body weight) to doses based on actual weight among obese ($BMI \geq 30 \text{ kg/m}^2$) patients undergoing autologous HCT for MM and lymphoma. The hypothesis of this study was that adjusting the conditioning regimen chemotherapy dose would result in reduced regimen-related toxicity and early mortality but would adversely affect long-term outcomes because of worse disease control.

The main findings were that most obese patients received dose-adjusted conditioning regimens, that adjusting doses did not appear to influence regimen-related toxicity, and that using actual weight to dose high-dose chemotherapy before HCT did not worsen OS in patients with either MM or lymphoma.

Single-center reports also found no differences in survival when comparing obese patients with MM [10] and lymphoma [11] who received dose-adjusted conditioning regimens with nonobese patient who received chemotherapy based on ABW.

Table 2
Causes of Death

Variable	Adjusted Body Weight	ABW
Number of patients	1933	544
Number of deaths	622 (32%)	174 (32%)
Cause of death		
Primary disease	465 (75%)	129 (74%)
Infection	22 (4%)	12 (7%)
Lung failure	9 (1%)	1 (<1%)
Other organ failure	19 (3%)	6 (3%)
Other	57 (9%)	18 (10%)
Not reported	50 (8%)	8 (5%)




Figure 2. Outcomes of patients with MM after autologous HCT using actual (unadjusted) weight and adjusted weight to calculate chemotherapy doses. Log-rank *P* values are shown in each panel. Outcomes include (A) TRM, (B) disease progression, (C) PFS, and (D) OS.




Figure 3. Outcomes of patients with lymphoma after autologous HCT using actual (unadjusted) weight and adjusted weight to calculate chemotherapy doses. Log-rank *P* values are shown in each panel. Outcomes include (A) TRM, (B) disease progression, (C) PFS, and (D) OS.

In contrast, a report of BEAM dosed on ABW for obese patients found no adverse effect on outcomes as well [12]. However, these are single-center studies with smaller numbers of patients and somewhat more uniform supportive care as compared with our registry-based study.

Our findings expand on a previous combined report from European Society for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry that compared the outcomes of obese patients with MM (BMI \geq 30; $n = 323$) with nonobese patients ($n = 764$) [13]. As in our study, most obese patients received reduced doses of chemotherapy, and there was no effect on mortality. In contrast to our study, however, patients who received a melphalan-only conditioning regimen ($n = 278$) did not have increased rates of early relapse. Albeit a small number ($n = 45$), obese patients who received a conditioning regimen of melphalan with total body irradiation ($n = 45$) had lower rates of relapse and mortality.

Additionally, our study showed that most obese patients with MM or lymphoma (78%), notwithstanding American Society for Blood and Marrow Transplant guidelines of melphalan dosing [5], received adjusted doses. The prevalence of obesity (BMI \geq 30 kg/m²) continues to increase in the general population [1,2]. The Centers for Disease Control and Prevention report that 36.7% of the US population is obese [3]. Concern over the most appropriate dosing strategy for the obese population led the American Society for Blood and Marrow Transplant to issue a position paper. However, paucity of data to inform the field remains a challenge [5]. The American Society of Clinical Oncology also issued guidelines for dose adjustment for chemotherapeutic agents [4], although these were not specific to transplant. The main concern with the American Society of Clinical Oncology guidelines was the frequent practice of underdosing chemotherapy in obese patients, resulting in worse control of disease. Historically, the use of IBW offers a simple way to approximate to lean body, which is more cumbersome to estimate [14]. Also, using lean body weight, or its surrogate, could be a safer way to precisely predict the pharmacokinetics. However, pharmacokinetics and pharmacodynamics also are influenced by age, gender, type of chemotherapy, and genetics, among other factors [4–6]. Even within the same chemotherapy the formulation needs to be considered, because pharmacokinetic studies of substitute captisol-stabilized for propylene glycol-free melphalan demonstrated a close to 10% increased systemic drug exposure compared with standard propylene glycol-based melphalan [15].

To better isolate the effect of chemotherapy dosing, the current study was limited to dosing strategies only in obese patients undergoing autologous HCT. The dose-adjustment strategy used varied depending on the transplant center, but most centers adjust the dose of the conditioning regimen in obese patients. This reflects the concerns of transplant physicians about the potential for increased toxicity of chemotherapy delivered based on ABW.

To assess the impact of conditioning regimen dose adjustment on toxicity in this study, the number of days hospitalized in the first 100 days post-HCT was used as a surrogate. Because many centers only hospitalize autologous HCT recipients during the administration of the conditioning regimen and others perform HCT as an outpatient procedure, we considered only patients who spent more than 7 of the first 100 days hospitalized. Overall, the length of hospitalizations was similar regardless of dose-adjustment strategy. However, when split by disease, patients with MM who received doses based on actual weight stayed longer in the hospital, based on a higher number of patients with more than 15 days in the hospital. This was mainly driven by the subset of patients with BMIs between 30

and 34 kg/m², perhaps because this was the largest group. This was not observed among patients with lymphoma. Our finding contrasts with a single-center report on 80 patients. That report observed longer hospitalizations and higher risks of grades 3 to 4 mucositis in patients with lymphoma who received a melphalan dose > 3.6 mg/kg [16]. One caveat on the comparison of both studies is that melphalan is typically dosed in mg/m², and when the dose is converted to mg/kg patients who are underweight rather than overweight are more frequently over the proposed threshold of 3.6 mg/kg.

The ideal assessment of regimen-related toxicity in autologous HCT would include detailed gastrointestinal side effects (mucositis, diarrhea), need for total parenteral nutrition, and infections. However, these were not available in the current study.

Because disease biology, post-HCT treatment management, autologous HCT goals, and treatment options at the time of disease relapse are different between MM and lymphoma, the outcomes analysis was performed for all patients and then separately for each disease group. After adjusting for center effect, there was no adverse effect of dose adjusting the conditioning regimen on overall mortality, TRM, and treatment failure for the entire population of the MM and lymphoma patient group studied separately.

However, the higher risk of early relapse in those who received dose-adjusted chemotherapy possibly reflects the loss of intensity of the conditioning regimen on disease control. Considering that both MM and lymphoma have effective salvage therapies, it is not unexpected that this increased risk of early relapse does not affect overall mortality.

In summary, most obese patients undergoing autologous HCT receive a dose-adjusted conditioning regimen. The practice of reducing the dose of the conditioning regimen in obese patients did not adversely affect mortality but did result in an increased risk of early relapse after autologous HCT. Thus, our findings do not support adjusting doses of conditioning regimens for obese patients with MM or lymphoma.

ACKNOWLEDGMENTS

The authors thank Jennifer Motl for assistance with the editorial review of the manuscript.

Financial disclosure: The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement [5U24CA076518](#) from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant/Cooperative Agreement [4U10HL069294](#) from NHLBI and NCI; contract HSH250201200016C with Health Resources and Services Administration; 2 grants ([N00014-17-1-2388](#) and [N0014-17-1-2850](#)) from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; *Amgen, Inc.; *Amneal Biosciences; *Angiocrine Bioscience, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Juno Therapeutics; Karyopharm Therapeutics, Inc.; Kite Pharma, Inc.; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Mediware; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; *Neovii

Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd. – Japan; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; and University of Minnesota. The asterisk indicates Corporate Members. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government.

Conflict of interest statement: There are no conflicts of interest to report.

SUPPLEMENTARY DATA

Supplementary data related to this article can be found online at [doi:10.1016/j.bbmt.2018.11.005](https://doi.org/10.1016/j.bbmt.2018.11.005).

REFERENCES

- Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. *Am J Prev Med*. 2012;42:563–570.
- US Department of Health and Human Services. *The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity*. 2001. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General.
- Centers for Disease Control and Prevention. Obesity and overweight. Available at: <https://www.cdc.gov/obesity/data/adult.html>. Accessed May 2018.
- Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2012;30:1553–1561.
- Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. *Biol Blood Marrow Transplant*. 2014;20:600–616.
- Jain R. Implications of obesity for drug therapy: limitations and challenges. *Clin Pharmacol Therap*. 2011;90:77–89.
- Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood*. 2005;106:2912–2919.
- Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. *J Clin Oncol*. 2005;23:3412–3420.
- Commenges D, Andersen PK. Score test of homogeneity for survival data. *Lifetime Data Anal*. 1995;1:145–156.
- Shultes KC, Arp C, Stockerl-Goldstein K, Trinkaus K, DeFrates S. Impact of dose-adjusted melphalan in obese patients undergoing autologous stem cell transplantation. *Biol Blood Marrow Transplant*. 2018;24:687–693.
- Bachanova V, Rogosheske J, Shanley R, et al. Adjusting cyclophosphamide dose in obese patients with lymphoma is safe and yields favorable outcomes after autologous hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2016;22:571–574.
- Fair C, Shanley R, Rogosheske J, et al. BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications. *Bone Marrow Transplant*. 2017;52:491–493.
- Vogl DT, Wang T, Perez WS, et al. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. *Biol Blood Marrow Transplant*. 2011;17:1765–1774.
- Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. *Ann Pharmacother*. 2000;34:1066–1069.
- Aljaitawi OS, Ganguly S, Abhyankar SH, et al. Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation. *Bone Marrow Transplant*. 2014;49:1042–1045.
- Costa LJ, Micallef IN, Inwards DJ, et al. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. *Br J Haematol*. 2008;143:268–273.